Research programme: Gram-negative infection bacteriocins - Novacta
Latest Information Update: 16 Jul 2016
At a glance
- Originator Unknown
- Developer Novacta
- Class Proteins
- Mechanism of Action Growth inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Gram-negative infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Gram-negative-infections in United Kingdom (Parenteral)